Toxic epidermal necrolysis secondary to Allopurinol usage
Keywords:
toxic epidermal necrolysis, toxicodermy, maculopapular lesions.Abstract
Introduction: Toxic epidermal necrolysis is an acute, rare process with high morbidity and mortality, characterized by necrosis and detachment of the epidermis in large cutaneous areas. Its etiology is mainly due to an abnormal immune reaction to different drugs against keratinocytes. The most significant clinical findings are maculopapular lesions that evolve to vesicles, affecting mainly the oral and conjunctival mucosas, as well as the genital area, but can affect the whole body including palms and soles, involving more than 30% of the body surface.
Objective: To describe the behavior of toxic epidermal necrolysis secondary to allopurinol use.
Case presentation: A 47-year-old male patient with a history of being treated with Allopurinol was presented. After four days, he started with palpebral edema, phlyctenas on his face, macular erythematous lesions disseminated on his neck, thorax and the inguinoscrotal region, as well as erythematous-ulcerous lesions that reached 37 % of total body surface.
Conclusions: The patient developed a nontraumatic acute cutaneous failure syndrome due to toxic epidermal necrolysis associated with the allopurinol use. He responded satisfactorily to the applied therapy despite the multiple complications suffered during his evolution.
Downloads
References
Mayorga JS, Jiménez AV, Sánchez AC. Síndrome de Stevens-Johnson y Necrólisis Epidérmica Tóxica, un reto diagnóstico y terapéutico. Rev Med Sinergia. 2020;5(1): 308.
Frey N, Jossi J, Bodmer M, Bircher A, Jick SS, Meier CR. The Epidemiology of Stevens Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. J Invest Dermatol. 2017;6;137(6):1240-7. DOI: https://doi.org/10.1016/j.jid.2017.01.031
Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020;9:F1000. DOI: https://doi.org/10.12688/f1000research.24748.1
Arora R, Pande RK, Panwar S, Gupta V. Drug-related Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review. Indian J Crit Care Med. 2021;25(5):575-9. DOI: https://doi.org/10.5005/jp-journals-10071-23826
Ueta M. Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis with Severe Ocular Complications. Front Med (Lausanne). 2021;8:651247. DOI: https://doi.org/10.3389/fmed.2021.651247
Hsieh MH, Watanabe T, Aihara M. Recent Dermatological Treatments for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Japan. Front Med (Lausanne). 2021;8:636924. DOI: https://doi.org/10.3389/fmed.2021.636924
White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, et al. SJS/TEN: Building Multidisciplinary Networks to Drive Science and Translation. J Allerg Clinic Immun. 2018 01;6(1):3869. DOI: https://doi.org/10.1016/j.jaip.2017.11.023
Patel TK, Patel PB, Thakkar S. Comparison of effectiveness of interventions in reducing mortality in patients of toxic epidermal necrolysis: A network meta-analysis. Indian J Dermatol Venereol Leprol. 2021;87(5):628-44. DOI: https://doi.org/10.25259/IJDVL_605_19
Wang Y, Chen C, Tassaneeyakul W, Saito Y, Aihara M, Choon SE, et al. The Medication Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison with the US FDA Label. Clinical Pharmacology & Therapeutics. 2018;105(1):112-20. DOI: https://doi.org/10.1002/cpt.1071
Arellano J, Álvarez D, Salinas MP, Molina I. Incidencia de síndrome de Stevens-Johnson y necrólisis epidérmica tóxica en Chile años 2001-2015 y su asociación con la latitud. Rev Med Chil. 2020;148(7):915-20. Spanish. DOI: https://doi.org/10.4067/S0034-98872020000700915
Stern RS, Divito SJ. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology, Thirty Years of Progress but Still Much to Be Done. J Invest Dermat. 2017;137(5):1004-8. DOI: https://doi.org/10.1016/j.jid.2017.01.003
Kuijper EC, French LE, Tensen CP, Vermeer MH, Bouwes Bavinck JN. Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN). J Eur Acad Dermatol Venereol. 2020;34(9):1957-71. DOI: https://doi.org/10.1111/jdv.16339
González-Herrada C, Rodríguez-Martín S, Cachafeiro L, Lerma V, González O, Lorente JA, et al. Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches. J Invest Dermat. 2017;137(10):20922100. DOI: https://doi.org/10.1016/j.jid.2017.05.022
Kara A, Devrim İ, Çağlar İ, Bayram N, Kundak S, Apa H. Stevens-Johnson syndrome and toxic epidermal necrolysis: a report of six cases. Turk J Pediatr. 2019;61(4):538-43. DOI: https://doi.org/10.24953/turkjped.2019.04.010
Downloads
Published
How to Cite
Issue
Section
License
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
